{"filing":{"accession_number":"0001193125-26-385225","cik":"0001869105","ticker":"BBOT","company_name":"BridgeBio Oncology Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"d97546d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/d97546d8k.htm"},"events":[{"id":32003,"run_id":29398,"accession_number":"0001193125-26-385225","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"BridgeBio disclosed new clinical trial data for its lead oncology programs (BBO-8520, BBO-11818, BBO-10203) and announced a strategic portfolio prioritization, deprioritizing certain programs (BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer) while focusing capital on higher-probability opportunities. This is a material operational and strategic business event—the company is reallocating resources based on clinical progress and competitive landscape—but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types. The disclosure includes encouraging efficacy data (75% ORR for BBO-8520 + pembrolizumab) and cash runway into 2028, both relevant to investor assessment of the company's prospects.","company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35061,"accession_number":"0001193125-26-385225","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BridgeBio disclosed new clinical trial data for its lead oncology programs (BBO-8520, BBO-11818, BBO-10203) and announced a strategic portfolio prioritization, deprioritizing certain programs (BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer) while focusing capital on higher-probability opportunities. This is a material operational and strategic business event—the company is reallocating resources based on clinical progress and competitive landscape—but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types. The disclosure includes encouraging efficacy data (75% ORR for BBO-8520 + pembrolizumab) and cash runway into 2028, both relevant to investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:21:48.618397+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35061,"accession_number":"0001193125-26-385225","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BridgeBio disclosed new clinical trial data for its lead oncology programs (BBO-8520, BBO-11818, BBO-10203) and announced a strategic portfolio prioritization, deprioritizing certain programs (BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer) while focusing capital on higher-probability opportunities. This is a material operational and strategic business event—the company is reallocating resources based on clinical progress and competitive landscape—but does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types. The disclosure includes encouraging efficacy data (75% ORR for BBO-8520 + pembrolizumab) and cash runway into 2028, both relevant to investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:21:48.618397+00:00","company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","filing_date":"2026-09-08"}]}